FIELD: medicine.
SUBSTANCE: present group of inventions relates to medicine, namely to neurology and psychiatry, and concerns application of cyclic amide for treating sigma-receptor mediated disorders. For that effective amount of compound of formula is introduced
.
EFFECT: it provides effective treatment of depression due to selective binding of said compound to sigma-2 receptors.
17 cl, 2 ex
| Title |
Year |
Author |
Number |
| METHODS FOR THE USE OF CYCLIC AMIDE DERIVATIVES FOR TREATMENT OF SIGMA-RECEPTOR-MEDIATED DISORDERS |
2011 |
- Luthringer, Remy, Henri
- Pellegrini, Lorenzo
- Karabelas, Argeris, N.
|
RU2746871C2 |
| METHODS FOR USING CYCLIC AMIDE DERIVATIVES FOR TREATING SCHIZOPHRENIA |
2011 |
- Lutringer Remi Anri
- Pellegrini Lorentso
- Karabelas Argeris N.
|
RU2576611C2 |
| MIXTURE CONTAINING CARBAMATE COMPOUND FOR PREVENTION, RELIEF OR TREATMENT OF SCHIZOPHRENIA |
2018 |
- Joung, Chan Mi
- Hwang, Sun Gwan
- Lee, Ji Won
- Jang, Young Koo
|
RU2772465C2 |
| NEW METHODS |
2014 |
- Vanover Kimberli
- Li Pen
- Mejts Sheron
- Devis Robert
- Uennogl Lourens P.
|
RU2682658C1 |
| THERAPEUTIC AGENTS |
2008 |
- Bilodo Mark T.
- Nanda Kausik K.
- Trotter B. Uehsli
|
RU2468025C2 |
| COMBINATIONS OF COMPOUNDS MODULATING THE NMDA RECEPTOR |
2015 |
|
RU2721948C2 |
| TREATMENT OF COGNITIVE DISORDERS WITH (R)-7-CHLORO-N-(QUINUCLIDIN-3-YL)BENZO[B]THIOPHENE-2-CARBOXAMIDE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF |
2014 |
- Kenig Gerkhard
- Chesuort Richard
- Shapiro Gideon
|
RU2662560C2 |
| USING ROLUPERIDONE TO TREAT NEGATIVE SYMPTOMS AND DISEASES, INCREASE NEUROPLASTICITY AND PROMOTE NEUROPROTECTION |
2019 |
|
RU2812786C2 |
| THERAPEUTIC AGENT FOR TREATING NEUROLOGICAL BEHAVIOUR DISORDERS AND METHOD OF TREATING NEUROLOGICAL BEHAVIOUR DEVELOPMENT DISORDERS |
2011 |
|
RU2536230C2 |
| TREATING COGNITIVE DISORDERS WITH (R)-7-CHLOR-N-(QUINUCLIDIN-3-YL) BENZO[b] THIOPHEN-2-CARBOXAMIDE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS |
2009 |
- Kenig Gerkhard
- Chesuort Richard
- Shapiro Gideon
|
RU2532327C2 |
